Taiwan: Taiwan does not recognise a deposit made in an international depositary

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Taiwan: Taiwan does not recognise a deposit made in an international depositary

As Taiwan is not a signatory to the Budapest Treaty, the effect of a deposit made in an international depositary under the Budapest Treaty is generally not recognised in Taiwan. Accordingly, even though a biological material has been deposited in an international depositary in order to meet the enabling requirement, the applicant is still required to make a corresponding deposit in a domestic depositary designated by the Taiwan Intellectual Property Office (TIPO). A late deposit will be deemed valid only if the certificates of deposit issued by both the international and domestic depositaries are filed before a statutory deadline, i.e. within four months from the filing date or sixteen months from the earliest priority date claimed, whichever is applicable. Further, in the event that a deposit is deemed invalid, the applicant may file a request for reinstatement of the deposit procedure within thirty days from the day following the cessation of the cause for delay.

For a patent application filed on December 29 2015 in Taiwan claiming the priority date of February 29 2014 from the counterpart US application with a deposit of biological material, the applicant needed to make a corresponding deposit at the domestic depositary to fulfil the enabling requirement. Accordingly, the applicant completed the necessary forms and submitted to the depositary the forms in which it was indicated that six vials of bacterial, i.e. the relevant biological material, are to be deposited in accordance with the Rules for Depositing Biological Materials. Upon perusal, the depositary suggested that a total of 25, instead of six vials, of bacteria be deposited. Thus, the applicant proceeded to make arrangements for the preparation of 19 additional vials of the bacteria on an urgent basis, but missed the four-month statutory deadline for filing with TIPO the certificates of deposit issued by an international depositary and the domestic depositary. The applicant then filed a request for reinstatement of the deposit procedure; however, the request was not entertained by TIPO. Against this unfavourable result, the applicant filed an appeal and, in turn, pursued the subsequent administrative litigation procedures.

The applicant argued that since it is time-consuming to prepare 19 additional vials of the bacteria to comply with the depositary's suggestion, he took it for granted that he could wait until the certificate of the deposit of all the 25 vials of the bacteria was available to file both the international and domestic certificates in a lump. The applicant also claimed that he had exercised all due diligence in complying with the depositary's suggestion, and the occurrence of the delay is not an event controllable and attributable to him.

On April 25 2019, the Supreme Administrative Court issued a final judgment upholding TIPO's decision that the deposit is invalid and cannot be reinstated as requested by the applicant. In its judgment, the Supreme Administrative Court interpreted "factors not attributable to the applicant" in a strict manner, indicating that only an event substantially corresponding to "the will of God" or "war" can be considered as a factor not attributable to the applicant. On top of this, the court held that the applicant should have at least deposited six vials of the bacteria in accordance with the Rules for Depositing Biological Materials and filed the international certificate of deposit in a timely manner.

This case suggests that inadvertent negligence might result in irreparable loss to the applicant. A patent practitioner should do his utmost to ensure that a patent application takes every required step towards becoming a patent and give sound advice to his clients when a patent practice in Taiwan is not in harmony with international practice.

lin.jpg

Ming-yeh Lin


Saint Island International Patent & Law Offices7th Floor, No. 248, Section 3Nanking East RoadTaipei 105-45, Taiwan, ROCTel: +886 2 2775 1823Fax: +886 2 2731 6377siiplo@mail.saint-island.com.twwww.saint-island.com.tw

more from across site and SHARED ros bottom lb

More from across our site

The firm is shaping its AI strategy around partnerships with Harvey and Legora alongside internally developed tools from its legal technology company, ELTEMATE
A dispute Down Under shows why trademark lawyers cannot afford to wait on the sidelines when a rival brand gathers momentum
The Third Circuit’s decision in Thomson Reuters v ROSS marks the first appellate-level decision addressing AI and fair use, prompting copyright counsel to consider arguments around potential licensing markets
Injunctions for HandsFree Labs and Align Technology come as the Court of Appeal warns that busy teams must have the staffing and resources to meet UPC deadlines
The chief technology officer remit, which has been created as the firm is building its litigation team, will include expanding the use of AI in patent and legal work and automating manual processes
Former Hoyng Rokh Moneiger partner Laura Alonso, who brought her team to ECIJA in March, discusses plans to expand further and why ECIJA’s ‘IP DNA’ is helping broaden her work
Amita Haylock discusses building an integrated Asia practice as clients increasingly demand that firms combine IP, technology and data expertise
François Pochart, Grégoire Desrousseaux and Lionel Martin, long-standing figures in the firm’s patent litigation team, are set to help launch a Paris-based litigation offering
The Unitary Patent has passed 100,000 registrations, but new data raises the question of whether 30% uptake is a ceiling or a staging post for further growth, say Michael Nielsen and Darren Smyth of EIP and Andrew Samm at Patently
The new generation of in-house IP leaders want commercial judgment, accessibility and flexibility, with AI raising expectations around both fees and delivery
Gift this article